Your SlideShare is downloading. ×
Sean Ekins cv
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Sean Ekins cv

1,664
views

Published on

curriculum vitae

curriculum vitae

Published in: Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,664
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Sean Ekins [email_address] Collaborations In Chemistry Resume
  • 2. Experience
    • Over 14 years of applied pharmaceutical company experience
    • Computational ( in silico ) drug discovery, QSAR and pharmacophore application, systems biology applied to pathway and biomarker discovery, in vitro methods, drug-drug interactions and computational ADME/TOX.
    • Successfully obtained NIH SBIR phase I and II grant funding as a principal investigator at different companies.
    • Valuable start-up company experience leading and managing teams of international scientists and collaborators, directing technology development and scientific research .
  • 3. Key Academic Qualifications
    • Nottingham Trent University
      • HND Science (Applied Biology)
    • University of Aberdeen
      • M.Sc. Clinical Pharmacology
      • Ph.D. Medicine and Therapeutics (Clinical Pharmacology)
      • D.Sc. Science
  • 4. Key Positions – Diversity of Experience
    • Post doc - Eli Lilly
      • 1996-1998
    • Research Scientist – Pfizer
      • 1998-1989
    • Senior Computational Chemist – Eli Lilly
    • 1999- 2001
    • Associate Director, Computational Drug Discovery - Concurrent Pharmaceuticals
      • 2001- 2004
    • Vice President, Computational Biology
      • 2004- 2006
    • Senior Consultant, Collaborations in Chemistry
      • 2007 - present
  • 5. Adjunct Positions
    • Adjunct Professor, Robert Wood Johnson Medical School, University of Medicine and Dentistry New Jersey, July 2007-present.
    • Adjunct Associate Professor, School of Pharmacy Department of Pharmaceutical Sciences, University of Maryland. MD, Jan 2005-present.
  • 6. Leadership Competencies
    • Collaboration and influencing: An outward facing scientist able to collaborate for mutual success and deliver on milestones.
    • Team leadership: An experienced cross-functional leader with effective communication skills.
    • Commercial orientation: Vast experience from pharma and biotech collaborations at identifying and obtaining opportunities for funding and applying leading edge technologies.
    • Results orientation: An intellectual and scientific risk taker who delivers beyond expectations.
    • Strategic orientation: Possesses a broad perspective of drug discovery and development.
  • 7. Strengths
    • Research innovation for drug discovery
      • Computational ADME/Tox Pioneer
      • Pharmacophore building expert
      • Broad cheminformatics skills for drug discovery
      • Technology development – e.g. MetaDrug which brought cheminformatics and systems biology together as an award winning commercial product
    • Writing papers and book chapters– over 150 since 1995
      • Many with over 100 citations
      • Web of Science h-factor = 33 (whatever value that has!)
    • Writing grants that get funded – 5 NIH grants to date as PI
    • Book Series editing for Wiley
    • Scientific Visionary – advocate of collaboration for over a decade
  • 8. Consulting For Clients
    • Collaborative Drug Discovery
      • www.collaborativedrug.com
      • BMGF funded grant on TB
      • STTR funded project
    • Merck
    • Longevica Pharmaceuticals
    • Ardelyx Pharmaceuticals
  • 9. Key Papers in 2010
    • Ekins S , Kaneko T, Lipinski CA, Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Ernst S, Yang J, Goncharoff N, Hohman M and Bunin BA, Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis, Mol BioSyst In Press 2010.
    • Rishi R. Gupta, Gifford, EM, Liston T, Waller CL, Hohman M, Bunin BA and Ekins S , Using open source computational tools for predicting human metabolic stability and additional ADME/Tox properties, Drug Metab Dispos, In Press, 2010.
    • Ekins S and Williams EJ, When Pharmaceutical Companies Publish Large Datasets: An Abundance of riches or fool’s gold?, Drug Disc Today, In Press 2010.
    • Ekins S , Gupta R, Gifford E, Bunin BA, Waller CL, Chemical Space: missing pieces in cheminformatics, Pharm Res, In Press 2010.
    • Kortagere S, Krasowski MD, Reschly EJ, Venkatesh M, Mani S and Ekins S , Evaluation of Computational Docking to Identify PXR Agonists in the ToxCastTM Database Env Health Perspect, In Press 2010.
    • Ekins S , Honeycutt JD and Metz JT, Evolving molecules using multi-objective optimization: applying to ADME/Tox, Drug Disc Today, 15: 451-460, 2010.
    • Arnold RJG and Ekins S , Time for cooperation in health economics among the modeling community, PharmacoEconomics, 28(8):609-613, 2010.
    • Ekins S . and Williams AJ, Reaching out to collaborators: crowdsourcing for pharmaceutical research, Pharm Res, 27: 393-395, 2010.
    • Ekins S and Williams AJ, Precompetitive Preclinical ADME/Tox Data: Set It Free on The Web to Facilitate Computational Model Building to Assist Drug Development. Lab On A Chip, 10: 13-22, 2010.
    • Zientek M, Stoner C, Ayscue R, Klug-McLeod J, Jiang Y, West M, Collins C and Ekins S , Integrated In Silico- In vitro strategy for addressing Cytochrome P450 3A4 time dependent inhibition, Chem Res Toxicol, 23: 664-676, 2010.
    • Ekins S , Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Hohman M and Bunin BA, A Collaborative Database and Computational Models for Tuberculosis Drug Discovery, Mol BioSyst, 6: 840-851, 2010.
  • 10. Books I have edited since 2006
  • 11. Editorial Positions
    • Associate Editor: Journal of Pharmacological and Toxicological Methods, since Jan 2001
    • Editorial Board: Drug Metabolism and Disposition, since 2003, Drug Discovery Today, since 2005, The Open Drug Delivery Journal 2007-2009, Current Drug Metabolism 2007-2009, Drug Metabolism Letters since 2007-2009. Pharmaceutical Research (Editor of Reviews) since 2009, Mutation Research-Reviews since 2009, The ChemSpider Journal of Chemistry 2009.
    • Editorial Advisory Board: Pharmaceutical Research, 2006-2008
  • 12. Grants
    • NIH Grants
    • 2R44GM069124-02 In Silico Assessment of Drug Metabolism and Toxicity, SBIR phase II (principal investigator) Funded (~$750,000 total cost) from 08/01/05 to 08/01/07.
    • 1R43NS061376-01 Targeted Aggregation Inhibitors for the Treatment of Amyloid Diseases, SBIR phase I (principal investigator) Funded ($124,425 total cost) from 10/01/07 to 03/31/2008
    • 1R43CA130183-01A1 Computer-Aided Design, Synthesis, And Testing Of A Novel Family Of Triazole-Based Anticancer Therapeutics, SBIR phase I (principal investigator) Funded (Total cost $114,818) From 05/01/08- 10/31/08
    • 1R43AI078763-01A1 Development of an Inhibitor of Toxoplasma gondii, NIAID Advanced Technology SBIR (principal investigator on proposal submitted then replaced upon leaving company) Funded (Total cost $638,000)
    • 1R41AI088893-01 Identification of novel therapeutics for tuberculosis combining cheminformatics, diverse databases and logic based pathway analysis, STTR phase I (Principal Investigator) Funded (Total cost $149,382) 07/01/11 – 06/30/11
    • European Grants
    • Part of the consortia for the framework grant More Medicines for Tuberculosis
    • Specific Programme “Cooperation” – Theme "Health"
    • Call identifier: FP7-HEALTH-2010-single-stage
    • Proposal No: 260872
    • Acronym: MM4TB
  • 13. Research Interests
    • Collaboration
    • Nuclear receptors (PXR, FXR, LXR, VDR modeling)
    • P450 modeling
    • Transporter modeling
    • hERG modeling
    • Crowdsourcing